Navigation Links
Study shows bone metastases treatment can improve overall survival
Date:11/15/2012

DENVER It is common for patients initially diagnosed with lung cancer to have the cancer spread to sites like the liver, brain and bone. One of the most frequent sites of metastases is the bone, with an estimated 30 to 40 percent of patients with non-small-cell lung cancer (NSCLC) developing bone loss. A study published in the December 2012 issue of the International Association for the Study of Lung Cancer's (IASLC) Journal of Thoracic Oncology, shows that the bone metastases drug denosumab was associated with improved overall survival compared with zoledonic acid (ZA).

A total of 811 lung cancer patients (411 for denosumab and 400 for ZA) were evaluated. Patients were randomized 1:1 to receive either monthly subcutaneous injection of denosumab 120 mg (plus intravenous infusion of placebo) or monthly intravenous infusion of ZA 4 mg (plus subcutaneous injection of placebo). The ZA dose was adjusted for renal impairment. And, daily calcium and vitamin D supplementation was strongly recommended for all patients.

In all 811 lung cancer patients, denosumab was associated with significally improved overall median survival compared with ZA, with a difference of 1.2 month. In patients with NSCLC, denosumab was associated with significant improved survival, with a difference of 1.5 months.

In addition, overall survival in patients with small-cell lung cancer was 7.6 months for the deno-sumab group and 5.1 months for the ZA group, a difference of 2.5 months. Denosumab-treated patients with squamous cell carcinoma also showed improved survival compared with the ZA group, with a difference of 2.2 months. The treatments were associated with similar overall survival in patients with adenocarcinoma.


'/>"/>

Contact: Kristal Griffith
Kristal.Griffith@iaslc.org
720-325-2952
International Association for the Study of Lung Cancer
Source:Eurekalert

Page: 1

Related medicine news :

1. Authors of landmark study on infant mortality and electronic medical records receive Garfield Award
2. Study Tracks Brain Gene Response to Territorial Aggression
3. Study shows different approach after progression in non-small cell lung cancer patients
4. Study reveals insights that could aid in therapeutic use of mesenchymal stem cells
5. Alcoholic Drinks Add 100 Calories a Day to Average Adults Diet: Study
6. Cash cuts increase smoking death risk for worlds poor, study says
7. Study finds asthma is not linked to lower educational attainment
8. RSV study shows potential for vaccine strategies to protect babies
9. Lyme Rash Reappearance Probably Signals New Infection, Study Says
10. Study finds reformulated ER Oxycodone abuse rates are significantly lower than original ER Oxycodone
11. Month of Birth Might Help Determine MS Risk, Study Suggests
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2016)... ... May 24, 2016 , ... Backed by decades ... for each job, ensuring the best suited solution to meet regulatory requirements. Their ... at their lab in Istanbul. , Metroloji Okulu specializes in MadgeTech’s line of ...
(Date:5/24/2016)... ... May 24, 2016 , ... ... Jonathan (Jon) Otterstatter to its board of directors. Otterstatter is co-founder, president ... the development of technological innovations that lead to broad-based healthcare solutions. , “Jon ...
(Date:5/24/2016)... ... May 24, 2016 , ... WaterAid launched the #perioddrama campaign to mark Menstrual ... 1 billion women around the world who do not have access to a toilet, even ... US about their dread of #perioddrama. The (sometimes hilarious) results help shine a light on ...
(Date:5/24/2016)... ... May 24, 2016 , ... ... patient Services To Begin In June , Aloria Health, specializing in a re-imagined, ... opening of Aloria Milwaukee, its first treatment facility for outpatient, day treatment and ...
(Date:5/24/2016)... , ... May 24, 2016 , ... ... tick-borne disease research and education, today announced that it has named Scott Santarella ... the Bonnie J. Addario Lung Cancer Foundation (ALCF) in San Francisco, where he ...
Breaking Medicine News(10 mins):
(Date:5/20/2016)... , May 20, 2016 The ... investors believe that the industry is not far from ... today ActiveWallSt.com featured the following four equities: Anacor Pharmaceuticals ... ATHX ), Aralez Pharmaceuticals Inc. (NASDAQ: ... INFI ). Sign up for your free trading ...
(Date:5/19/2016)... , May 19,2016 Cellvizio ... Digestive Disease Week Meeting and 91 st ... Mauna Kea Technologies (Euronext: MKEA, OTCQX: MKEAY) ... platform, today announced that its Cellvizio platform is ... on gastroenterology during the month of May. The ...
(Date:5/19/2016)... , The data will be presented in ... The conclusions of the study point to a ... 90% of the m presenting duration ... of the patients had clinical benefit.     ... study of plitidepsin in combination with bortezomib and dexamethasone in patients with relapsed ...
Breaking Medicine Technology: